BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34818560)

  • 1. Environmental factors modulating protein conformations and their role in protein aggregation diseases.
    Devi S; Chaturvedi M; Fatima S; Priya S
    Toxicology; 2022 Jan; 465():153049. PubMed ID: 34818560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteostasis impairment in protein-misfolding and -aggregation diseases.
    Hipp MS; Park SH; Hartl FU
    Trends Cell Biol; 2014 Sep; 24(9):506-14. PubMed ID: 24946960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular protein homeostasis in neurodegenerative diseases.
    Wilson MR; Satapathy S; Vendruscolo M
    Nat Rev Neurol; 2023 Apr; 19(4):235-245. PubMed ID: 36828943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways of cellular proteostasis in aging and disease.
    Klaips CL; Jayaraj GG; Hartl FU
    J Cell Biol; 2018 Jan; 217(1):51-63. PubMed ID: 29127110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling protein aggregation as an ageing related process or a neuropathological response.
    Trigo D; Nadais A; da Cruz E Silva OAB
    Ageing Res Rev; 2019 May; 51():67-77. PubMed ID: 30763619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis.
    Walker AC; Bhargava R; Dove AS; Brust AS; Owji AA; Czyż DM
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha 1-Antitrypsin Deficiency: A Disorder of Proteostasis-Mediated Protein Folding and Trafficking Pathways.
    Karatas E; Bouchecareilh M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteostasis and Proteotoxicity in the Network Medicine Era.
    Lualdi M; Alberio T; Fasano M
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein folding, misfolding, aggregation and their implications in human diseases: discovering therapeutic ways to amyloid-associated diseases.
    Iram A; Naeem A
    Cell Biochem Biophys; 2014 Sep; 70(1):51-61. PubMed ID: 24639112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Misfolding Diseases.
    Hartl FU
    Annu Rev Biochem; 2017 Jun; 86():21-26. PubMed ID: 28441058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.
    Lindquist SL; Kelly JW
    Cold Spring Harb Perspect Biol; 2011 Dec; 3(12):. PubMed ID: 21900404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluc-EGFP reporter mice reveal differential alterations of neuronal proteostasis in aging and disease.
    Blumenstock S; Schulz-Trieglaff EK; Voelkl K; Bolender AL; Lapios P; Lindner J; Hipp MS; Hartl FU; Klein R; Dudanova I
    EMBO J; 2021 Oct; 40(19):e107260. PubMed ID: 34410010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanochaperone-Based Strategies to Control Protein Aggregation Linked to Conformational Diseases.
    Caballero AB; Gamez P
    Angew Chem Int Ed Engl; 2021 Jan; 60(1):41-52. PubMed ID: 32706460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ER chaperone-metal interactions: links to protein folding disorders.
    Tiffany-Castiglioni E; Qian Y
    Neurotoxicology; 2012 Jun; 33(3):545-57. PubMed ID: 22370090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical kinetics for drug discovery to combat protein aggregation diseases.
    Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Trends Pharmacol Sci; 2014 Mar; 35(3):127-35. PubMed ID: 24560688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.